Service Predicts Tablet Tooling Sticking Problems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Service Predicts Tablet Tooling Sticking Problems



I Holland has announced the TSAR Predict service, which offers a solution to stop tablet tooling sticking problems, the company reports. The service examines the API or main component of a formulation and prepares a solution by reviewing factors including Van Der Waals, capillary action and morphology. The service was developed after the completion of a two-year Tableting Science Anti-Stick Research (TSAR) project in collaboration with the University of Nottingham's School of Pharmacy and professionals from the Laboratory of Biophysics and Surface Analysis in the UK. The aim of the project was to investigate and solve the universal tablet-manufacturing problem of sticking. The information has now resulted in a service that forecasts the correct anti-stick PharmaCote coating solution for any formulation.

Source: I Holland

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here